Table 1.
Baseline clinical characteristics of study patients according to implant technique
|
Characteristics |
Total sample |
Implant technique |
P
value |
|
|---|---|---|---|---|
| |
|
PP |
IoP |
|
| (n =1176) | (n =132) | (n = 1044) | ||
| Age, years |
|
|
|
|
| Mean (SD) |
66.2 (6.5) |
67.8 (5.9) |
66.0 (6.5) |
|
| Median |
67.0 |
68.0 |
67.0 |
|
| Range |
45.0–80.0 |
50.0–79.0 |
45.0–80.0 |
|
| 95% CI |
65.9–66.6 |
66.8–68.8 |
65.6–66.4 |
0.002* |
| PSA, ng/ml |
|
|
|
|
| Mean (SD) |
7.4 (3.1) |
8.6 (3.8) |
7.2 (3.0) |
|
| Median |
6.7 |
7.6 |
6.6 |
|
| Range |
0.6–22.0 |
0.7–20.0 |
0.6–22.0 |
|
| 95% CI |
7.2–7.6 |
7.9–9.2 |
7.1–7.4 |
<0.001* |
| PSA, n (%) |
|
|
|
|
| ≤ 10 |
980 (83.3) |
94 (71.2) |
886 (84.9) |
|
| > 10 |
196 (16.7) |
38 (28.8) |
158 (15.1) |
<0.001** |
| Gleason score, |
|
|
|
|
| Mean (SD) |
5.9 (0.6) |
5.3 (0.8) |
6.0 (0.5) |
|
| Median |
6.0 |
5.0 |
6.0 |
|
| Range |
3.0–7.0 |
3.0–7.0 |
3.0–7.0 |
|
| 95% CI |
5.91–5.98 |
5.2–5.5 |
5.9–6.1 |
<0.001* |
| Gleason score < 7, n (%) |
1044 (88.8) |
128 (97.0) |
916 (87.7) |
0.002** |
| Prostate volume, ml |
|
|
|
|
| Mean (SD) |
38.4 (9.6) |
35.0 (9.1) |
38.8 (9.6) |
|
| Median |
38.0 |
35.0 |
39.0 |
|
| Range |
10.0–74.0 |
13.0–57.0 |
10.0–74.0 |
|
| 95% CI |
37.8–68.9 |
33.4–36.6 |
38.2–39.4 |
<0.001* |
| Clinical stage, n (%) |
|
|
|
|
| T1-T2a |
1086 (92.3) |
113 (85.6) |
973 (93.2) |
|
| > T2a |
56 (4.8) |
14 (10.6) |
42 (4.0) |
0.001** |
| ADT, n (%) |
442 (37.6) |
54 (40.9) |
388 (37.2) |
0.4** |
| EBRT, n (%) |
132 (11.2) |
4 (3) |
128 (12.3) |
0.002** |
| Follow-up, months |
|
|
|
|
| Mean (SD) |
51.8 (35.1) |
80.5 (43.5) |
48.1 (32.1) |
|
| Median |
47.0 |
83.0 |
47.0 |
|
| Range |
1.0–155.0 |
3.0–155.0 |
1.0–132.0 |
|
| 95% CI | 49.7–53.8 | 72.9–87.9 | 46.2–50.1 | <0.001* |
*Mann–Whitney test, α < 0.05; **Chi-square test, α < 0.05.
PP, Preplanning; IoP, Intraoperative planning; PSA, Prostate-specific antigen; ADT, Androgen deprivation therapy; EBRT, External beam radiation.